Controlled market release of Proteomics’ Promarker®D and Promarker®Eso in WA and NT commences today, Monday 14 September 2026, under Proteomics International’s exclusive pathology distribution agreement with Healius.
The controlled release in WA and NT will support operational and systems readiness ahead of national rollout.
Highlights
Proteomics International is pleased to announce the controlled market release of Promarker®D and Promarker®Eso in WA and NT, under Proteomics International’s exclusive pathology distribution agreement with Healius Limited (ASX: HLS) for all Promarker® tests.
Operational and systems readiness with Healius progressing to support national rollout.
Broader commercial sales expected to follow in Q2 FY27, subject to successful completion of implementation activities.
Australian patient pricing has been initially set at $495 for Promarker®D and $997 for Promarker®Eso. The tests will initially be available on a private-pay basis.
Promarker®Endo assay refinement activities are progressing, with achievement of the next clinical milestone subject to successful completion of the validation program.
View ASX Announcement: here